- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02045069
Efficacy and Safety of Ivermectin Against Dengue Infection
October 29, 2015 updated by: Mahidol University
A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection
This is a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Ivermectin in Children and Adult patients with Dengue Infection.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Patients with confirmed dengue infection who meet all inclusion and exclusion criteria will be enrolled in the study and admitted in the hospital.
Patients will be randomly assigned in a pre-specified ratio of 1:1:1 to one of the following study groups: ivermectin 200-400 µg/kg single daily dose for 2 days, ivermectin 200-400 µg/kg single daily dose for 3 days, or placebo.
Tablets of ivermectin or placebo will be administered for 3 days.
Clinical exam will be performed daily during hospitalization and blood samples will be collected for hematology, clinical chemistry, serology, viral load and quantitative nonstructural 1 (NS1) antigen.
Safety assessment will be conducted during admission.
Patients will be discharged one day after fever subsidence and will be asked to return 2 weeks after first dose of study medication for safety assessment and blood sampling.
Study Type
Interventional
Enrollment (Anticipated)
360
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yupin Supputamonkol, MD.
- Phone Number: 6681-754-5573
- Email: ysuputtamongkol@gmail.com
Study Contact Backup
- Name: Panisadee Avirutnan, MD, PhD.
- Phone Number: 6681-895-0019
- Email: panisadee.avi@mahidol.ac.th
Study Locations
-
-
-
Bangkok, Thailand, 10700
- Recruiting
- Faculty of Medicine Siriraj Hospital, Mahidol University
-
Contact:
- Nasikarn Angkasekwinai, MD
- Phone Number: 66818708766
- Email: nasikarn@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults ages of 15 or greater.
- History or presence of fever (temperature > 38°C) of ≤ 72 hr duration.
- Clinical suspicion of dengue infection such as high fever without an evidence or suspected focus of infection on clinical examination.
- Positive NS 1 strip assay
Exclusion Criteria:
- Clinically significant abnormal laboratory results which are deemed to be unassociated with dengue infection
- Clinical evidence or a history of significant respiratory, metabolic, renal, hepatic, hematologic or chronic diseases
- History of autoimmune, immune dysfunction disorder or taking warfarin
- Clinical suspicion of any bacterial infection
- Pregnancy and lactating women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo once daily for 3 days
|
Experimental: 2 days Ivermectin
Ivermectin 200 - 400 µg/kg once daily for 2 days
|
200-400 µg/kg once daily for 2 days and placebo once daily at D3
Other Names:
|
Experimental: 3 days Ivermectin
Ivermectin 200-400 µg/kg once daily for 3 days
|
200 -400 µg/kg once daily for 3 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to resolution of viremia
Time Frame: Every 12 hr, from date of randomization until resolution of viremia or until fever subsides for 1 day, whichever came first.
|
Every 12 hr, from date of randomization until resolution of viremia or until fever subsides for 1 day, whichever came first.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to clearance of NS1 antigen
Time Frame: Every 12 hr, from date of randomization until resolution of viremia or until fever subsides for 1 day, whichever came first.
|
Every 12 hr, from date of randomization until resolution of viremia or until fever subsides for 1 day, whichever came first.
|
Time of subsidence of fever
Time Frame: From date of randomization until fever subsides
|
From date of randomization until fever subsides
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Panisadee Avirutnan, MD, PhD., Division of Dengue Hemorrhagic Fever Research Department of Research and Development, Faculty of Medicine Siriraj Hospital Mahidol University, Bangkok 10700, THAILAND
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (Anticipated)
February 1, 2016
Study Completion (Anticipated)
March 1, 2016
Study Registration Dates
First Submitted
January 13, 2014
First Submitted That Met QC Criteria
January 22, 2014
First Posted (Estimate)
January 24, 2014
Study Record Updates
Last Update Posted (Estimate)
November 1, 2015
Last Update Submitted That Met QC Criteria
October 29, 2015
Last Verified
October 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ESIDEN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dengue Fever
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseaseVietnam
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesPeru
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesMexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic FeverSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesThailand
-
Sanofi Pasteur, a Sanofi CompanyUnited States Department of DefenseCompletedDengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
U.S. Army Medical Research and Development CommandGlaxoSmithKlineCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Shock SyndromePuerto Rico
-
SanofiCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue VirusUnited States
-
SanofiCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusAustralia
Clinical Trials on 2 days Ivermectin
-
Clinical Research Centre, MalaysiaCompleted
-
University of the Balearic IslandsNot yet recruiting
-
Pierre Fabre DermatologyWithdrawn
-
Jennifer KeiserNational Centre for Parasitology, Entomology and Malaria Control, CambodiaCompletedStrongyloides Stercoralis InfectionCambodia
-
Copenhagen Academy for Medical Education and SimulationCompletedSimulation | Laparoscopy | Skills AcquisitionDenmark
-
State University of New York at BuffaloCompleted
-
Assiut UniversityUnknownPost-Gastrointestinal Tract Surgery Malnutrition